Maxcyte (MXCT) Change in Accured Expenses (2020 - 2026)

Maxcyte (MXCT) has reported Change in Accured Expenses for 7 consecutive years, with -$3.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 34.93% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$1.8 million (up 57.74% YoY), while the FY2025 annual figure was -$3.7 million, down 97.61% from the prior year.
• Change in Accured Expenses climbed to -$3.6 million in Q1 2026 per MXCT's latest filing, from -$3.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.6 million in Q2 2025 and bottomed at -$5.6 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$494647.1 across 5 years, with a median of -$48400.0 in 2022.
• On a YoY basis, Change in Accured Expenses climbed as much as 136233.33% in 2023 and fell as far as 3800.17% in 2023.
• Maxcyte's Change in Accured Expenses stood at $976600.0 in 2022, then tumbled by 103.69% to -$36000.0 in 2023, then slumped by 1186.11% to -$463000.0 in 2024, then sank by 693.52% to -$3.7 million in 2025, then rose by 1.01% to -$3.6 million in 2026.
• Business Quant data shows MXCT's Change in Accured Expenses at -$3.6 million in Q1 2026, -$3.7 million in Q4 2025, and -$21000.0 in Q3 2025.